To: Board of Supervisors
From: Dr. Grant Colfax, Health Services Director
Report Title: Purchase Order with Abbvie US LLC
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute, on behalf of the Health Services Director, a purchase order with Abbvie US LLC in an amount not to exceed $825,000 and Letter of Commitment for the purchase of breast implants for Contra Costa Regional Medical Center (CCRMC), for the period from October 1, 2025 through September 30, 2028.
FISCAL IMPACT:
Approval of this action will result in expenditures of up to $825,000 over a three-year period and will be funded by Hospital Enterprise Fund I revenues.
BACKGROUND:
Abbvie US LLC, through its subsidiary Allergan Aesthetics, markets the Natrelle line of breast implants. These implants are available in both silicone-filled and saline-filled options and are intended for breast augmentation as well as breast reconstruction. Certain textured implant models, specifically the BIOCELL line, were voluntarily recalled worldwide due to safety concerns. Abbvie also offers a warranty program, ConfidencePlus, on some implant models, which may cover replacement and other costs under defined conditions.
Breast implants are important for CCRMC to have on hand for surgical procedures because they are essential for breast reconstruction surgeries following mastectomy, injury, or congenital abnormalities. They allow surgeons to restore breast shape, symmetry, and volume, which can significantly improve a patient’s physical appearance, psychological well-being, and quality of life. Having implants readily available ensures that reconstruction surgeries can be performed promptly without delays, supporting better patient outcomes and efficient surgical workflow. Additionally, the availability of different implant types and sizes allows surgeons to tailor procedures to each patient’s specific needs.
Abbvie US LLC is a supplier of the Vizient Group Purchasing Organization (GPO), which means that CCRMC, a Vizient member, is eligible to receive rebates and access lower pricing. This purchase is governed by the Vizient Supplier Agreement entered into between Vizient Supply, LLC and Abbvie US LLC on October 1, 2025 (Agreement No. MS7693).
During the renewal process it was discovered that there were discrepancies between the spending reported by Vizient and the supplier resulting in CCRMC’s placement in an incorrect pricing tier. The negotiations with the vendor to reconcile the discrepancies resulted in delays, but ultimately an agreement was reached, requiring the County to sign a Letter of Commitment to activate the appropriate rebate levels. The Letter of Commitment obligates the County to indemnify and hold harmless Abbvie US LLC for any sales, use, value added and other similar taxes, including any interest, penalties or other additions thereon, applicable to the transactions contemplated by the Agreement.
Approval of this action is essential to ensure the timely procurement of the necessary breast implants, enabling CCRMC to perform scheduled breast reconstruction and augmentation surgeries without delays, maintain optimal patient care, and support surgical teams with the required resources for successful outcomes.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, CCRMC will face delays in performing breast reconstruction and augmentation surgeries, which could impact patient care, extend recovery timelines, and limit the surgical team’s ability to provide timely and effective treatment.